Management of Thrombocytopenia in Pregnancy

Diagnosis and Initial Evaluation

• The diagnosis of immune thrombocytopenic purpura (ITP) in pregnancy requires exclusion of pregnancy-specific causes, including gestational thrombocytopenia, preeclampsia, HELLP syndrome, DIC, folate deficiency, massive obstetrical hemorrhage, acute fatty liver, and antiphospholipid antibody syndrome, as recommended by the American Society of Hematology 1, 2
• Bone marrow examination is not required to diagnose ITP in pregnancy, according to the American College of Obstetricians and Gynecologists 2
• Antiplatelet antibody testing has no value in routine diagnosis, as stated by the American Society of Hematology 2
• Blood pressure and liver function tests should be obtained to exclude preeclampsia, as recommended by the National Institute of Child Health and Human Development 3

Treatment Thresholds by Trimester

• Treatment is indicated when platelet count is <20,000-30,000/μL, even if asymptomatic, or when there is any symptomatic bleeding, regardless of platelet count, as recommended by the American College of Obstetricians and Gynecologists 1, 2, 4
• Patients with platelets ≥30,000/μL do not routinely require treatment in the first two trimesters, according to the American Society of Hematology 1, 2

First-Line Treatment Options

• Prednisone 10-20 mg/day is recommended as initial treatment, adjusted to minimum dose maintaining hemostatic platelet count, as stated by the American College of Rheumatology 2, 4
• IVIg is used when corticosteroids are ineffective, significant side effects occur, or more rapid platelet increase is required, as recommended by the American Society of Hematology 2, 4, 5

Management of Delivery

• The mode of delivery should be determined by obstetric indications alone, not by maternal platelet count, as recommended by the American College of Obstetricians and Gynecologists 6, 5
• Prophylactic platelet transfusions before delivery are appropriate when platelets <10,000/μL with planned cesarean section or epistaxis or mucous membrane bleeding and expected vaginal delivery, as stated by the American Society of Hematology 3

Neonatal Management

• Check neonatal platelet count for 3-4 days after birth, and consider brain imaging if platelet count at birth is <20,000/μL, as recommended by the American Academy of Pediatrics 3
• IVIg is appropriate if infant's platelets <20,000/μL without evidence of intracranial hemorrhage, as stated by the American Society of Hematology 3

Management of Immune Thrombocytopenia in Pregnancy

Treatment Options

• For non-splenectomized Rh(D)-positive patients, IV anti-D 50-75 μg/kg is effective and safe in the second and third trimesters, with augmentation with corticosteroids or IVIg usually required to achieve target platelet count of 50 × 10⁹/L 7
• Combining first-line treatments in the weeks before delivery is considered for patients failing first-line therapy 7
• High-dose methylprednisolone (1000 mg) possibly combined with IVIg or azathioprine is considered for patients failing first-line therapy 7
• Azathioprine is safe during pregnancy based on SLE and renal transplantation data, though response is slow 7
• Cyclosporin A has not been associated with significant maternal or fetal toxicity 7

Refractory Cases and Delivery Management

• Splenectomy is best performed in the second trimester if necessary, and may be performed laparoscopically, though technically difficult beyond 20 weeks' gestation 7
• Appropriate vaccination during or after pregnancy is required after splenectomy 7
• The mode of delivery should be determined by obstetric indications alone, not by maternal platelet count, as there is no evidence that cesarean section is safer for the thrombocytopenic fetus than uncomplicated vaginal delivery 7
• The neonatal mortality rate for babies born to mothers with ITP is less than 1%, with intracranial hemorrhage occurring in only 0-1.5% of thrombocytopenic infants 7

Critical Pitfalls to Avoid

• Fetal blood sampling by cordocentesis should not be performed as it carries a 1-2% fetal mortality risk, at least as high as the risk of intracranial hemorrhage 7
• Fetal or neonatal platelet count cannot be reliably predicted by maternal platelet count, platelet antibody levels, or history of maternal splenectomy 7
• Most hemorrhagic events in neonates occur 24-48 hours after delivery at the nadir of the platelet count, not during delivery itself 7

Management of Thrombocytopenia in Pregnancy

Diagnostic Evaluation and Treatment

• The American Society of Hematology recommends that regional anesthesia considerations should be made when platelet count drops below 50,000/μL, with careful risk-benefit analysis and multidisciplinary discussion 8
• For counts below 50,000/μL, spinal may be safer than epidural blockade due to smaller needle size and decreased risk of vascular damage 8
• Monitor the trend as well as absolute value—rapidly falling counts require closer observation than stable low counts 8
• Procedures to avoid during labor include fetal scalp electrodes, fetal blood samples, ventouse delivery, and rotational forceps due to increased fetal hemorrhagic risk 8

Neonatal Management

• The American Academy of Pediatrics recommends checking cord blood platelet count at delivery by clean venepuncture of cord vessel, not by draining blood from cord 8
• Monitor neonatal platelet counts for 3-4 days after birth as counts typically nadir at 24-48 hours (days 2-5) after delivery 8
• Avoid intramuscular injections (including vitamin K) until platelet count is known 8
• IVIg 1 g/kg is recommended for neonatal platelets <20,000/μL without evidence of intracranial hemorrhage 8
• Life-threatening hemorrhage requires platelet transfusion combined with IVIg 8
• Perform transcranial ultrasonography on neonates with platelet counts <50,000/μL at delivery 8
• Exclude neonatal alloimmune thrombocytopenia by laboratory testing when severe neonatal thrombocytopenia and hemorrhage are present 8
• Neonatal thrombocytopenia secondary to maternal ITP may last for months and occasionally requires a second dose of IVIg at 4-6 weeks after birth 8

Special Considerations

• Despite thrombocytopenia, ITP in pregnancy may be associated with a prothrombotic state due to anticardiolipin antibody syndromes or other pregnancy-related factors, and VTE prophylaxis should be considered 8
• In ITP, the second fetus is usually as affected as the first (unlike alloimmune thrombocytopenia where fetal thrombocytopenia tends to worsen in subsequent pregnancies) 8

Management of Immune Thrombocytopenia in Pregnancy

Introduction to Treatment

• The American Society of Hematology recommends prednisone 10-20 mg/day as initial treatment for Immune Thrombocytopenia in pregnancy, adjusted to the minimum dose that maintains a hemostatically effective platelet count 9

Pharmacological Considerations

• Prednisone is metabolized by placental 11-beta-hydroxylase, providing a protective barrier for the fetus that limits fetal exposure, making it safer than dexamethasone or methylprednisolone in pregnancy 9
• Dexamethasone and betamethasone are fluorinated corticosteroids that cross the placenta more readily with minimal metabolism, making them less ideal for maternal ITP treatment 9

Treatment Algorithm

• Start prednisone 10-20 mg/day orally, titrating to the minimum effective dose, and avoid aggressive tapering in the final weeks before delivery 9
• Monitor for corticosteroid complications including hypertension, hyperglycemia, osteoporosis, excessive weight gain, and psychosis 9

Second-Line Therapy

• IVIg is the preferred second-line agent when corticosteroids are ineffective, cause significant side effects, or when rapid platelet increase is required 9
• IVIg can be repeated as single infusions as needed to maintain safe platelet counts for delivery 9

Treatment Thresholds

• Initiate treatment when platelet count falls below 20,000-30,000/μL, even if asymptomatic 9
• Aim for platelet count ≥50,000/μL for cesarean section 9
• Target ≥75,000/μL if regional anesthesia (epidural/spinal) is desired, though some hematologists consider ≥50,000/μL adequate 9

Critical Pitfalls to Avoid

• Do not use dexamethasone or betamethasone as routine first-line therapy for maternal ITP due to lack of metabolic protection 9
• Avoid rituximab, danazol, TPO-receptor agonists, and most immunosuppressive drugs (except azathioprine) due to teratogenicity concerns 9
• Do not taper prednisone aggressively in the final weeks before delivery, as platelet counts commonly drop during the third trimester 9

Multidisciplinary Coordination

• Optimal management requires collaboration among hematology, obstetrics, anesthesia, and neonatology 9

Management of Immune Thrombocytopenia (ITP) in Pregnancy

Diagnostic Criteria and Exclusion

• Pregnancy‑specific causes such as preeclampsia/HELLP, DIC, acute fatty liver, and antiphospholipid syndrome must be excluded before diagnosing ITP in pregnant patients 10.
• Bone‑marrow examination is not required for confirming ITP in pregnancy 10.
• Testing for antiplatelet antibodies provides no diagnostic value in this setting 10.

Monitoring Strategy

• In the first and second trimesters, platelet counts can be observed without treatment when they are ≥30 × 10⁹/L and the patient is asymptomatic 10.

Treatment Thresholds for Delivery

• A platelet count ≥50 × 10⁹/L is considered sufficient for both vaginal delivery and cesarean section 11.
• For epidural or spinal anesthesia, a higher target of ≥75 × 10⁹/L is preferred by anesthesiologists (some hematologists accept ≥50 × 10⁹/L) 11.

First‑Line Therapy

• Prednisone 10–20 mg orally daily is the preferred initial agent; dose should be titrated to the lowest amount that maintains a hemostatic platelet count [11][12].
• Clinicians must monitor for maternal side‑effects such as hypertension, hyperglycemia, osteoporosis, weight gain, and psychosis while on prednisone [11][12].

Second‑Line / Refractory Therapy

• Intravenous immunoglobulin (IVIg) is indicated when corticosteroids are ineffective, cause intolerable side‑effects, or a rapid platelet rise is needed 13.
• Combining prednisone with IVIg achieves a therapeutic response in ≈80 % of refractory cases [12][13].
• High‑dose methylprednisolone (≈1 g) may be used, alone or together with IVIg or azathioprine, for patients unresponsive to standard prednisone [12][13].
• IV anti‑D (50–75 µg/kg) is an option for Rh(D)‑positive, non‑splenectomized women in the second or third trimester, usually alongside corticosteroids or IVIg [12][13].
• Azathioprine is considered safe (based on systemic lupus erythematosus and transplant experience) and may be employed for refractory disease [12][13].
• Splenectomy is rarely required; when performed, the optimal timing is the second trimester, preferably via laparoscopy [12][13].

Medications to Avoid in Pregnancy

• Vinca alkaloids and danazol are contraindicated 11.
• Rituximab, TPO‑receptor agonists, and most other immunosuppressive agents (except azathioprine) should be avoided because of teratogenic risk [11][12].

Delivery Planning

• The mode of delivery should be dictated solely by obstetric indications, not by maternal platelet count 13.
• Evidence shows no advantage of cesarean section over uncomplicated vaginal delivery for thrombocytopenic fetuses 13; neonatal mortality is <1 %, and intracranial hemorrhage occurs in 0–1.5 % of affected infants 13.

Neonatal Management

• At birth, obtain a cord‑blood platelet count by clean venipuncture of a cord vessel 13.
• Monitor neonatal platelet counts for 3–4 days postpartum, as nadir typically occurs between 24–48 hours after delivery 13.

Common Pitfalls (Diagnostic, Therapeutic, and Delivery Errors)

• Diagnostic errors: failing to exclude preeclampsia/HELLP, ordering unnecessary bone‑marrow biopsies, or attempting to predict fetal platelet counts from maternal values 10.
• Therapeutic errors: aggressive tapering of prednisone in the weeks before delivery 11 and use of teratogenic drugs such as rituximab, TPO‑agonists, or danazol 11.
• Delivery errors: performing cesarean section solely because of low maternal platelets, using fetal cordocentesis to assess fetal platelet count, or employing traumatic obstetric instruments (scalp electrodes, forceps, vacuum) 13.